Screener
Rhythm Pharmaceuticals, Inc. RYTM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Net loss | $(55,639) | $(49,498) |
| Accrued dividends on convertible preferred stock | (1,104) | (1,322) |
| Net loss attributable to common stockholders | $(56,743) | $(50,820) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.83) | $(0.81) |
| Weighted-average common shares outstanding, basic and diluted | 67,974,193 | 63,059,165 |
| Net loss | $(55,639) | $(50,820) |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustment | 1,784 | (2) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s EPS (diluted)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported EPS (diluted) of -$0.83 in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s EPS (diluted) decreased by 2.5% year-over-year, from -$0.81 to -$0.83.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s EPS (diluted) has grown at a 23.0% compound annual growth rate (CAGR), from -$1.36 to -$3.11.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude